

PROUDLY HOSTED BY



World class cancer care. Close to home.

2nd Annual BREAST CANCER SYMPOSIUM

Controversies in Breast Cancer: Increasing or Decreasing?

September 25-26, 2020 LIVE Online Event

THIS ACTIVITY HAS BEEN APPROVED FOR

11 *AMA PRA
Category 1 Credits™*

ACCREDITED PROVIDER



EDUCATIONAL PARTNERS



ACTIVITY PLANNED BY



2nd Annual BREAST CANCER SYMPOSIUM

Controversies in Breast Cancer: Increasing or Decreasing?

PRESENTATION DOWNLOAD

The accredited content presented during the conference will be posted online for viewing and download within 30 days after the conference. An email will be sent to all participants with viewing and download instructions. Not all presentations will be shared due to reprint and permission restrictions.



HOW TO CLAIM CREDIT

- Log in each day on the conference platform.
- You will be emailed instructions for completing the post-test, program evaluation, claiming credit and printing your certificate within 7 days following the conference.



FOR QUESTIONS OR TECHNICAL ASSISTANCE

Email BCS@mymededco.com

Dear Breast Cancer Symposium Attendees:

It is my pleasure to welcome you to New York Oncology Hematology's 2nd Annual Breast Cancer Symposium. We wish we could be together in person in the beautiful Hudson Valley of upstate New York at this time of year, moving from summer into the autumn season. However, the virtual format this year has allowed more of you to attend from afar!

This conference expresses the passion and compassion of our conference Course Chair and Moderator, Dr. Maria Theodoulou, for the holistic care of women with breast cancer. Ever grounded in science, with rapidly evolving data of translational research trials, and delivered by an esteemed faculty in the breast cancer world.

We thank our event sponsors for their support to bring this conference to you.

Thank you so much for attending and we look forward to an exciting and enriching engagement together!

Sincerely,

A handwritten signature in black ink, appearing to be 'Ira Zackon', with a stylized loop and a horizontal line extending to the right.

Ira Zackon, MD
Conference Planning Committee Co-Chair and
President, New York Oncology Hematology

Dear Colleagues,


During these unprecedented times, it is with heartfelt gratitude and pride that New York Oncology Hematology is hosting the 2nd Annual Breast Cancer Symposium via a live web cast that will reach our regional colleagues as well as national colleagues.

When the planned live program in June 2020 was canceled due to the coronavirus pandemic every one of the speakers enthusiastically agreed to move forward with a web-based program. And here it is. The agenda is comprised of nationally and internationally known speakers as well as our regional thought leaders. We will hear about updates that have impacted the clinical pathways available for patients diagnosed with breast cancer in the early setting as well as the advanced setting, novel ways of dissecting an individual patient's breast cancer diagnosis and how to optimize the patient's treatment protocol.

Although moving forward in our personal lives has slowed, science has gratefully kept on track without delay, continuing to move forward with research from bench to clinic. For two days we will have conversations that will educate and excite us all for when we meet our patients again in our respective clinics.

Thank you for being part of this educational event. Thank you for seeing the dream of excellence continue.

Sincerely,

A handwritten signature in black ink, appearing to read 'M Theodoulou', with a stylized, cursive script.

Maria Theodoulou, MD, Program Chair
New York Oncology Hematology

2nd Annual BREAST CANCER SYMPOSIUM

Controversies in Breast Cancer: Increasing or Decreasing?

The Conference is being held in Eastern Daylight Time



Friday, September 25th, 2020

10:00 AM	EXHIBITS	
10:15 AM	Non-CME Session: Navigating the HER2+ Breast Cancer Treatment Landscape: A Case-Based Clinical Discussion	Dr. Brian Leyland-Jones (National Foundation for Cancer Research)
11:15 AM	Non-CME Session: A CDK 4 & 6 Inhibitor With Overall Survival Data for Women With HR+, HER2-Metastatic Breast Cancer, Including Those Likely to Do Worse	Dr. Peter Kaufman (University of Vermont Cancer Center, Burlington)
12:00 PM	Welcome, Opening Remarks & Arena Survivorship Award	Dr. Maria Theodoulou (NYOH) Dr. Ira Zackon (NYOH)
12:30 PM	COVID19 & The Physician	Dr. Marc Citron (ProHEALTH)
1:00 PM	Breast Imaging: Current & Future	Dr. Elizabeth Morris (MSKCC)
1:30 PM	EXHIBITS & BREAK	
1:45 PM	Community Driven Breast Imaging	Dr. Beth Whiteside (CCP)
2:15 PM	Hereditary Risk Factors in 2020	Dr. Mark Robson (MSKCC)
2:45 PM	Metabolic & Energy Balance Perturbations in Breast Cancer Pathogenesis & Treatment	Dr. Neil Iyengar (MSKCC)
3:45 PM	EXHIBITS & BREAK	
4:00 PM	Advances in the Management of Hormone Positive Early Breast Cancer	Dr. Francis Arena (NYU)
4:30 PM	Assessing Risk for Breast Cancer & Intervention	Dr. Andrew Seidman (MSKCC)
5:00 PM	Advances in the Management of Hormone Positive Metastatic Breast Cancer	Dr. Claudine Isaacs (Georgetown)
5:30 PM	EXHIBITS & BREAK	
5:45 PM	Breast Cancer & The Older Patient	Dr. Hyman Muss (UNC)
6:15 PM	Triple Negative Breast Cancer Management in 2020: Looking Back & Looking Ahead	Dr. Tiffany Traina (MSKCC)
6:45 PM	DAY 1 CLOSING REMARKS	Dr. Maria Theodoulou (NYOH)
6:55 PM	Non-CME Session: Innovative Oral Treatment Options for Patients: HR+/HER2- mBC or gBRCA Mutated Triple-Negative and HR+/HER2- mBC	Dr. Anne Porter O'Dea (University of Kansas Cancer Center)

Saturday, September 26th, 2020

7:00 AM	EXHIBITS	
8:00 AM	Opening Remarks	Dr. Maria Theodoulou (NYOH)
8:05 AM	What Do We Do With the Lymph Nodes after Neo-Adjuvant Chemotherapy: Case Discussion	Dr. Eleftherios Mamounas (UF) Dr. Loren Rourke (US Oncology)
8:35 AM	Immunotherapy and Breast Cancer	Dr. George Plitas (MSKCC)
9:05 AM	Breast Reconstruction in the Setting of Adjuvant Radiation	Dr. Joseph Disa (MSKCC)
9:35 AM	Radiation Therapy After Neoadjuvant Chemotherapy	Dr. Todd Doyle (NYOH)
10:05 AM	Hypofractionation If At All	Dr. Yasmin Hasan (UOC)
10:35 AM	EXHIBITS & BREAK	
10:50 AM	KEYNOTE LECTURE: What is Cancer?	Dr. Larry Norton (MSKCC)
11:50 AM	EXHIBITS	
12:00 PM	Non-CME Session: Updates on the Treatment of Patients With Unresectable or Metastatic HER2+ Breast Cancer Who Previously Received Anti-HER2 Therapies	Dr. Marc Citron (ProHEALTH)
1:00 PM	Tailoring Adjuvant Therapy for Early Stage HER2+ Breast Cancer	Dr. Edith Perez (MAYO)
1:30 PM	HER2NEU Metastatic Breast Cancer	Dr. Chau Dang (MSKCC)
2:00 PM	DAY 2 CLOSING REMARKS	Dr. Maria Theodoulou (NYOH)
2:10 PM	Non-CME Session: TUKYSA® (tucatinib): A New Treatment Option for Patients with HER2+ Metastatic Breast Cancer	Dr. Virginia Kaklamani (UT Health)

GOAL

Advances in breast cancer health have been growing exponentially during the twenty-first century and identification of novel therapeutic strategies have led to improved surgical and radiation outcomes. Actionable targets have identified smarter systemic therapies with improved, disease-free, overall survival benefits. In addition to awareness, addressing the health, emotional, and physical well-being of patients after breast cancer treatment have improved the overall quality of life for the patient and their families.

As breast cancer is a multimodal disease, the purpose of this conference is to present the multiple facets that constitute the individual patient's diagnosis, management, and treatment. The goal of this conference is to educate the medical and global community in a forum to foster communication that will benefit the individual patient as well as the community.

TARGET AUDIENCE

Medical, surgical, and radiation oncologists as well as primary care physicians, gynecologists, medical professionals and health care professionals with an interest in breast cancer are invited to attend.

LEARNING OBJECTIVES

After completing this activity, participants will be able to:

- Review the modern surgical approaches addressed in the patient encounter
- Discuss updates in breast cancer imaging for earlier detection
- Identify therapeutic advances in early and advanced hormone receptor-positive, HER2neu overexpressing and triple negative breast cancer
- Review advances in radiation therapy and outcomes
- Identify risk factors and endocrine interventions in patients high risk for developing breast cancer
- Discuss the role of hereditary genetics and the implication to the patient and their families

FEE INFORMATION

The fee for this educational activity is \$250 for physicians and \$50 for all other allied health professionals.

ACCREDITATION INFORMATION

Accreditation Statement:

This activity has been planned and implemented in accordance with the accreditation require-



AT THE FOREFRONT
**UChicago
Medicine**

ments and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The University of Chicago Pritzker School of Medicine and New York Oncology Hematology, PC, and in collaboration with myMedEd, Inc. The University of Chicago Pritzker School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement:

The University of Chicago Pritzker School of Medicine designates this live activity for a maximum of 11.0 **AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses and other healthcare professionals will receive a Certificate of Participation. For information on the applicability and acceptance of Certificates of Participation for educational activities certified for **AMA PRA Category 1 Credits™** from organizations accredited by the ACCME, please consult your professional licensing board.

Assurance of Balanced, Unbiased, and Fair Content:

It is the policy of The University of Chicago Pritzker School of Medicine to ensure balance, independence, objectivity, and scientific rigor in all its individually provided or jointly provided educational activities. Individuals who are in a position to control the content of any educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Mechanisms to ensure that presentations are free from commercial bias are in place. Faculty will also disclose any off-label and/or investigational use of pharmaceuticals or instruments discussed in their presentation.

PLANNING COMMITTEE

Maria Theodoulou, MD **(Course Chair & Moderator)**

Medical Oncologist, Breast Cancer Medicine
New York Oncology Hematology
Albany, NY

Ira Zackon, MD

New York Oncology Hematology – President
Hematologist/Medical Oncologist
NYOH Hematology Stem Cell Transplant Program,
NYOH Albany Medical Center
Clinical Assistant Professor
Albany Medical College
Albany, NY

FACULTY

Francis Arena, MD

Director, NYU Langone Arena Oncology
Clinical Professor,
NYU Health Medical College
President and Director of Research,
Sass Foundation for Medical Research
Lake Success, NY

Marc Citron, MD

Clinical Professor of Medicine
Donald and Barbara Zucker School of
Medicine at Hofstra/Northwell
Chief, Breast Cancer
Chair Emeritus, Department of
Oncological Services
ProHEALTH Care
Lake Success, NY

Chau T. Dang, MD

Medical Director,
MSK Westchester Medical Oncology
Attending, Breast Medicine Service
Memorial Sloan Kettering Cancer Center
New York, NY

Joseph J. Disa, MD, FACS

Attending Plastic Surgeon
Vice Chair of Clinical Activities,
Department of Surgery
Benno C. Schmidt Chair in Surgical Oncology
Memorial Sloan Kettering Cancer Center
New York, NY

Todd Doyle, MD

Director of Radiation Therapy
New York Oncology Hematology
Albany, NY

Yasmin Hasan, MD

Associate Professor
Department of Radiation & Cellular Biology
Residency Program Director
Director of Gynecological Brachytherapy
University of Chicago Medical Center
Chicago, IL

Claudine Isaacs, MD

Professor of Medicine and Oncology
Associate Director, Clinical Research
Leader, Clinical Breast Cancer Program
Georgetown University
Washington, DC

Neil Iyengar, MD

Assistant Attending
Memorial Sloan Kettering Cancer Center
Associate Attending
Rockefeller University
Assistant Professor of Medicine
Weill Cornell Medicine
New York, NY

Eleftherios (Terry) Mamounas, MD, MPH

Medical Director,
Comprehensive Breast Program
Orlando Health UF Health Care Center
Professor of Surgery
University of Central Florida
Orlando, FL

Elizabeth Morris, MD

Chief, Breast Imaging Service
Larry Norton Chair and Professor of
Radiology
Weill Cornell Medical College
Memorial Sloan Kettering Cancer Center
New York, NY

Hyman B. Muss, MD

Mary Jones Hudson Distinguished
Professor of Geriatric Oncology
Professor of Medicine
University of North Carolina
Director of Geriatric Oncology
Lineberger Comprehensive Cancer Center
Chapel Hill, NC

Larry Norton, MD, FASCO, FAACR

Senior Vice President,
Office of the President
Medical Director
Evelyn H. Lauder Breast Center
Deputy Director for Clinical and
Translational Science
MSK Comprehensive Cancer Center
Norna S. Sarofim Chair of Clinical Oncology
New York, NY

Edith A. Perez, MD

Professor of Medicine
Director, Breast Cancer Translational
Genomics Program
Mayo Clinic
Jacksonville, FL

George Plitas, MD

Associate Attending, Breast Service
Department of Surgery
Memorial Sloan Kettering Cancer Center
New York, NY

Mark E. Robson, MD

Chief, Breast Medicine Service
Attending Physician, Breast Medicine and
Clinical Genetics Services
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, NY

Loren L. Rourke, MD, MHCM, FACS

Chief Surgical Officer
US Oncology Network
The Woodlands, TX

Andrew Seidman, MD

Medical Director
Bobst International Center
Attending Physician
Breast Medicine Service
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, NY

Tiffany A. Traina, MD

Vice Chair, Oncology Care
Department of Medicine
Associate Attending Physician
Section Head, Triple Negative Breast
Cancer Clinical Research Program
Memorial Sloan Kettering Cancer Center
Associate Professor of Medicine
Weill Cornell Medicine
New York, NY

Beth E. Whiteside, MD

Community Care Physicians
Assistant Professor of Radiology
Medical Director Breast Care Center
Albany Medical Center
Albany, NY

PLANNING COMMITTEE BIOGRAPHIES



Maria Theodoulou, MD (Course Chair & Moderator)

Dr. Theodoulou is recognized internationally for her breast cancer research. Prior to joining NYOH, she was an attending physician in the Department of Medicine at Memorial Sloan Kettering Cancer Center on the Breast Medicine Service, and a Professor of Medicine at the Joan and Sanford Weill Medical College of Cornell University, both in New York City. Her research has included HER2neu directed clinical research, conjugated antibody research, androgen receptor positive triple negative targeted clinical trials, feasibility and phase 3 trials in the elderly in the early breast cancer setting and novel molecules in advanced breast cancer. She has mentored multiple residents and fellows, and has lectured extensively in the U.S. and chaired international symposiums and lectured in Bangkok, India, Japan, Hong Kong, and Europe. She has received multiple awards, as well as a Lifetime Achievement Award from the country of Cyprus, the Hally Yaccino Steiner Award from the Susan G. Komen Breast Cancer Foundation, as well as the Lifetime Achievement Award from the Hellenic Medical Society in New York in 2016. Dr. Theodoulou was named Leading Physicians of the World, Breast Cancer Medicine, 2019.

Dr. Theodoulou, a long-time weekender in the Southern Berkshires where she and her husband have owned a home, moved up to the country full time in 2016. Unable to give up her passion for taking care of patients, she joined NYOH seeing patients in Albany and Hudson, New York. She is now collaborating with her colleagues to continue developing a center of excellence for the treatment of breast cancer and addressing women's health issues.



Ira Zackon, MD

Ira Zackon, MD, is a Hematologist/ Oncologist and Director of the Stem Cell Transplant Program and President of New York Oncology Hematology, PC (NYOH) and assistant clinical professor at Albany Medical College in Albany, New York.

After earning a medical degree in 1986 from McGill University in Montreal, Quebec, Canada, he completed an internship and residency in medicine at Royal Victoria Hospital in Montreal in 1987. Dr. Zackon completed fellowships in Hematology/Medical Oncology at Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire (1990-1992), and Northwestern University Medical Center, Chicago, Illinois (1992-1994).

At NYOH, Dr. Zackon has developed the practice's autologous stem cell transplant program, expanded collaborative care for allogeneic bone marrow transplant patients at NYOH with regional transplant centers, and focused NYOH participation in research trials in the hematologic malignancies through the US Oncology Network and the Blood Cancer Research Partnership in association with the Dana-Farber Cancer Institute in Boston, Massachusetts.

FACULTY BIOGRAPHIES



Francis Arena, MD

Francis P. Arena, MD, FACP received his Bachelor of Science Degree from Fordham University and his Medical Degree from Cornell University Medical College. His internship and residency were carried out at New York Hospital/Memorial Hospital, after which Dr. Arena served as Chief Medical Resident and later as Hematology/Oncology Fellow at the Memorial Sloan-Kettering Cancer Center. He was also assistant to Chairman of Medicine for education at Memorial Sloan Kettering Cancer Center. He is Board Certified in Internal Medicine and in Medical Oncology. Today Dr. Arena is Clinical Professor of Medicine at New York University and Adjunct Clinical Assistant Professor of Medicine at Cornell University Medical College. He is the Director of the NYU Langone Arena Oncology Center in Lake Success, NY.

Because of his keen interest in cancer research, Dr. Arena helped establish and is the president of the SASS Foundation for Medical Research, which supports medical fellows at a number of hospitals. He is on the Advisory Board of "1 in 9", the Breast Cancer Coalition, and serves as a consultant for numerous pharmaceutical companies.

continued →

Dr. Arena is widely published and has lectured extensively in his field. He is an Assistant Editor of the journal *Oncology* and previously on the Editorial Board of the *Community Oncology* journal. Dr. Arena has been the recipient of multiple awards and citations for his work in oncology and breast cancer. Some of these awards include the David award given by *Networking* magazine, The Eileen Dryer Award by the Sass Foundation, the Il Leone de San Marco award in medicine by the Italian-American league of Westchester and the Bronx and has been cited in repeated years as one of the top oncologists in the New York Metropolitan area by the *Castle Connolly* magazines and *Newsday*. Recipient of the inaugural Francis P. Arena Humanitarian Award by the New York Oncology Hematology Foundation in 2019. Frank lives with his wife and wonderful children in Long Island, NY.



Marc L. Citron, MD

Dr. Citron received his undergraduate degree from Brandeis University. A native of Detroit, he then completed medical school at Wayne State University. He subsequently relocated to Washington DC where he completed his medical internship and residency at Georgetown University Medical Center. After serving as Chief Medical Resident, he was awarded the Daryl Rubenstein Fellowship in Medical Oncology at Georgetown's Vincent Lombardi Cancer Center.

After his fellowship, Dr. Citron spent three more years in Washington honing his laboratory and clinical investigation skills. In the 1980s, he moved to New York as Head of Long Island Jewish Medical Center's Medical Oncology Section. Specializing in breast cancer, he conducted translational laboratory research in DNA repair and clinical investigation while maintaining a busy practice and teaching. In 1997 he was appointed Professor of Medicine at the Albert Einstein College of Medicine. Shortly thereafter, he left LIJ to join the original group of partners at ProHEALTH, a new multispecialty group headquartered in Long Island where he was the Director of Cancer Services and Chief of Breast Cancer. ProHEALTH is now one of the largest integrated group practices in New York.

In 2011 he became Clinical Professor of Medicine at the newly-established, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell.

As principal investigator in the early 2000s for National Cancer Institute Protocol C9741, Dr. Citron collaborated with Dr. Norton and CALGB colleagues in a groundbreaking study that established dose-dense chemotherapy as one of the leading adjuvant treatments for breast cancer.

Dr. Citron is now chair emeritus department of Oncological Services and chief of breast cancer at ProHEALTH.



Chau T. Dang, MD

With an interest in evaluating combination therapies that include anti-HER2 drugs with chemotherapy in the treatment of patients with early-stage and metastatic HER2-positive breast cancer, Dr. Dang focuses on developing more effective and less toxic treatment strategies for women with this disease. Her research and an investigator-initiated trial at Memorial Sloan Kettering has led to the widespread use and National Comprehensive Cancer Network (NCCN) endorsement of a dose-dense, anthracycline/taxane-containing chemotherapy regimen followed by trastuzumab in patients with early stage HER2-positive breast cancer. A second investigator-initiated study that evaluated dual anti-HER therapy with trastuzumab and pertuzumab and chemotherapy for patients with HER2-positive metastatic breast cancer led to the NCCN endorsement of this regimen as a standard option in treating patients with metastatic HER2-positive breast cancer. A third investigator-initiated study on dual anti-HER2 therapy with trastuzumab and lapatinib with chemotherapy also had an impact on research worldwide. Dr. Dang and her colleagues are currently leading other research trials, both locally and internationally that focus on the unique cardiac toxicities of anthracyclines and anti-HER2 agents. To allow for improved patient selection and monitoring, she studies cardiac biomarkers, with a future goal of facilitating early interventions to minimize acute and late cardiac effects of cancer treatment.

Dr. Dang is board-certified in internal medicine and medical oncology with clinical expertise in breast cancer. She received her MD at the Medical University of South Carolina followed by Internal Medicine Residencies at Allegheny General Hospital/Medical College of Pennsylvania and Fellowships in Hematology/Oncology at Memorial Sloan Kettering Cancer Center.



Joseph J. Disa, MD, FACS

Joseph J. Disa, MD is a reconstructive microsurgeon specializing in oncologic reconstruction at Memorial Sloan Kettering Cancer Center. He is an Attending Surgeon at MSKCC and Professor of Surgery at Weill Cornell Medical College. He holds the Benno C. Schmid Chair in Surgical Oncology and serves as the Vice Chair of Clinical Activities in the Department of Surgery. Dr. Disa has a significant presence in the MSKCC regional network and is Surgical Director at both the Westchester and Bergen County campuses. Dr. Disa's clinical and research interests center around breast reconstruction after mastectomy, although he performs all types of cancer reconstructive surgery. Outside of MSKCC, Dr Disa is the Section Editor for Breast for the journal Plastic and Reconstructive Surgery. He is a past president of the Northeastern Society of Plastic Surgeons and the American Society of Reconstructive Microsurgery. He is also a former Director of the American Board of Plastic Surgery.



Todd Doyle, MD

Dr. Doyle was trained as a radiation oncologist at the Mallinckrodt Institute of Radiology and the Hospital of the University of Pennsylvania. He is currently the director of radiation oncology and a board member with New York Oncology Hematology PC. He is a Susan G. Komen Honoree for the treatment of breast cancer and has published on the treatment of breast cancer in the *International Journal of Radiation Oncology Biology and Physics*. He has served as a written and oral examiner for the American Board of Radiology as well as on numerous other academic and administrative committees. Current interests include novel modalities in the delivery of radiation therapy including SRS and SBRT in addition to the treatment of breast cancer.




Yasmin Hasan, MD

Yasmin Hasan, MD, Associate Professor of Radiation Oncology, specializes in the treatment of breast and gynecologic cancers. She uses highly targeted, localized radiation techniques – such as brachytherapy and intensity-modulated radiotherapy (IMRT) – to minimize damage to the healthy tissue surrounding a malignancy.

Dr. Hasan's research focuses on finding patterns in breast cancer and gynecologic cancer outcomes, with the goal of developing preventative therapies and improving definitive treatment.

An accomplished author, Dr. Hasan has published several articles in peer-reviewed journals and contributed to book chapters on the role of external beam radiation in the management of malignant diseases.



Claudine Isaacs, MD

Dr. Claudine Isaacs is a Professor of Medicine and Oncology, Associate Director of Clinical Research, and Leader of the Breast Disease Group at the Lombardi Comprehensive Cancer Center (LCCC) at Georgetown University. She is also the Medical Director of the Jess and Mildred Fisher Center for Hereditary Cancer and Clinical Genomics Research. She has extensive experience in the conduct of clinical trials focusing on all aspects of breast cancer and currently serves as Co-Chair Endocrine Resistance Working Group of the Translational Breast Cancer Research Consortium (TBCRC) and as Co-Chair of the Clinical Trials Operations Working Group for the I-SPY 2 Trial. She has authored over 200 peer-reviewed publications and edited two textbooks. She has served on a number of national committees including the Cancer Education and the Scientific Program Committees at ASCO, the Breast Oncology Local Diseases Task Force of the Breast Steering Committee of the NCI, and the ASCO Breast Cancer Guideline Advisory Group.



Neil Iyengar, MD

Dr. Neil Iyengar is a board-certified Medical Oncologist and clinical-translational researcher at Memorial Sloan Kettering Cancer Center (MSKCC) where he specializes in the care of patients with breast cancer. He also holds joint research appointments at the Rockefeller University Center for Clinical and Translational Science and Weill Cornell Medicine in New York. Dr. Iyengar is a National Cancer Institute Principal Investigator and an American Cancer Society Research Scholar. Dr. Iyengar received his undergraduate and medical degrees from the University of Illinois at Chicago accelerated degree program where he graduated with the College's highest honors (University Scholar). He completed residency training in Internal Medicine at the University of Chicago Medical Center followed by fellowship in medical oncology and hematology at MSKCC. As a faculty member on the Breast Medicine Service at MSKCC, Dr. Iyengar has received numerous awards for his work including Young Investigator and Career Development Awards from the Conquer Cancer Foundation of the American Society of Clinical Oncology. He has published numerous original research articles in high impact journals and has been an invited speaker at several international conferences.

Dr. Iyengar's research focuses on methods to improve cardiometabolic health as a strategy to prevent breast cancer and improve response to cancer therapy. His group is testing the anti-cancer effects of structured exercise and nutritional interventions in women and men at high risk or diagnosed with breast cancer. Dr. Iyengar's research is also investigating the use of drugs that treat metabolic disorders, such as diabetes and obesity, to improve the effectiveness of cancer therapies. Based on his research, Dr. Iyengar's clinical practice is focused on improving the lifestyle of people affected by cancer. He is now leading the launch of an exciting new clinical program, the Optimal Living and Wellness Program, which seeks to enhance all aspects of wellbeing using a scientific and highly personalized approach during and after cancer therapy.



Eleftherios (Terry) Mamounas, MD, MPH

Terry P. Mamounas, MD, is Medical Director of the Comprehensive Breast Program at Orlando Health UF Health Cancer Center, Professor of Surgery at University of Central Florida and Clinical Professor of Clinical Sciences at Florida State University. He is past Chair of the NSABP Breast Committee and current Chair of the NRG Oncology Breast Committee.

Dr. Mamounas received his medical degree from the University of Athens Medical School in Athens, Greece, and a Masters of Public Health degree in Epidemiology from the University of Pittsburgh. He completed his surgical residency at McKeesport Hospital in McKeesport, Pennsylvania, an oncology research fellowship at the University of Pittsburgh and a surgical oncology fellowship at Roswell Park Cancer Institute in Buffalo, New York.

Dr. Mamounas has authored or co-authored over 400 abstracts, manuscripts, and book chapters, and he has given numerous presentations on breast cancer at various regional, national, and international symposia. His clinical research has focused on the surgical and adjuvant treatment of early-stage breast cancer. He is a member of several professional societies including the American College of Surgeons, the Society of Surgical Oncology, the American Society of Clinical Oncology and the American Society of Breast Surgeons. Dr. Mamounas is a member of the NCI Breast Cancer Steering Committee. He serves on several editorial boards and he is past associate editor for the Journal of Clinical Oncology. Dr. Mamounas is a past member of the Scientific Advisory Council for the Susan G. Komen for the Cure.



Elizabeth Morris, MD

Elizabeth Morris, MD is Professor of Radiology at Weill Cornell Medical College (WCMC), Chief of the Breast Imaging Service at Memorial Sloan Kettering Cancer Center (MSKCC), and the Larry Norton Endowed Chair. Dr. Morris graduated summa cum laude from the University of California Davis (UCD) in Biochemistry and received her medical degree from the University of California, San Francisco (UCSF). She completed her residency at WCMC and a body/breast imaging fellowship at MSKCC where she has since remained on faculty.

Dr. Morris is a fellow of the American College of Radiology (ACR), Society of Breast Imaging (SBI) and International Society of MR in Medicine (ISMRM) and is past president of the SBI. She is the inaugural Equity Diversity & Inclusion officer of the ISMRM and co-chair of the Women of ISMRM (WISMRM).

continued →

Her research focus is on how best to use newer techniques such as MRI for early breast cancer detection and to improve the workup of breast lesions. In collaboration with her colleagues, she has written over 200 papers, 40 chapters, and 4 books about breast disease with an emphasis on the use of MRI. She has lectured widely both nationally and internationally at over 300 conferences. She has mentored over 50 international research fellows. She has grants from NCI, RSNA, Komen Foundation, and Breast Cancer Research Foundation. She has authored a book *Breast MRI: Diagnosis & Intervention*. Her recent research efforts have involved looking at imaging biomarkers to assess risk and treatment response.



Hyman B. Muss, MD

Hyman B. Muss MD is an experienced clinician-scientist, the Mary Jones Hudson Distinguished Professor of Geriatric Oncology at the University of North Carolina School of Medicine, and the Director of the Geriatric Oncology Program at the UNC Lineberger Comprehensive Cancer Center Program. His interest is education and research focused on cancer in older patients and is an internationally recognized leader in this area. His particular interest and research expertise is in the care of breast cancer patients with a focus on the management of older women. He also has a major interest in breast cancer survivorship and long-term toxicity of treatment. After working with his previous UNC colleague, Dr. Ned Sharpless, he is exploring the role of biomarkers of aging and their potential role as predictors of toxicity and survival. Dr. Muss has developed and been PI of multiple clinical and translational trials including lead author of an NCI-sponsored intergroup trial that compared standard care with oral chemotherapy in older women with early stage breast cancer and which for the first time showed the value of chemotherapy in this older populations. He serves as the mentor for medical students, medicine residents, junior faculty, and more recently Geriatric Oncology fellows. He previously co-chaired the Alliance Committee on Cancer in Older Adults. He has been co-chair of the Breast Committee for the CALGB, Chair and a member of the board of Directors of the American Board of Internal Medicine, and a member of the Board of Directors of the American Society of Clinical Oncology (ASCO) and the ASCO Foundation. He was awarded the B.J. Kennedy Award in Geriatric Oncology by ASCO, the Susan G. Komen for the Cure Brinker Award for Scientific Distinction in Clinical Research, and an honorary Doctor of Science Degree from his alma mater, Lafayette College. He has served in the U.S. Army in Vietnam where he was awarded the Bronze Star medal.



Larry Norton, MD, FASCO, FAACR

Dr. Larry Norton, MD, Norna S. Sarofim Chair of Clinical Oncology and Senior Vice President, Memorial Sloan Kettering Cancer Center, and Medical Director of the Evelyn H. Lauder Breast Center is Professor of Medicine, Weill-Cornell Medical College. He is a founder of the Breast Cancer Research Foundation and has served as its Scientific Director since the Foundation's inception in 1993. Dr. Norton has served on or chaired numerous committees of the National Cancer Institute, National Institutes of Health, and the Institute of Medicine of the National Academy of Sciences and has served as President of the American Society of Clinical Oncology among other leadership roles in that and other organizations. He is also a Fellow of the American Society of Clinical Oncology and of the American Association for Cancer Research Academy.

Dr. Norton has dedicated his life to the eradication of cancer by activities in medical care, laboratory and clinical research, advocacy and government. His research is broad but he is best known for mathematical modeling in therapeutic development. He has been involved in the development of several effective agents including paclitaxel and trastuzumab. He co-invented the Norton-Simon Model of cancer growth which has broadly influenced cancer therapy, and more recently the self-seeding concept of cancer metastasis and growth. He is the Principal Investigator of an NCI Program Project Grant in Models of Human Breast Cancer and an author of more than 350 published articles and many book chapters.

Among many honors, he received ASCO's Karnofsky and Bonadonna Awards, the McGuire Lectureship at the San Antonio Breast Cancer Symposium, MSKCC's Whitmore Award for Clinical Excellence, the Columbia University's Gold Medal for Outstanding Achievement in Medical Research, The Cold Spring Harbor Laboratory Double Helix Award as well as the Thomson Reuters Highly Cited Researcher Certificate.



Edith A. Perez, MD

Edith A. Perez, MD, is the Serene M. and Frances C. Durling Professor of Medicine at Mayo Clinic College of Medicine. Dr. Perez is a cancer specialist and an internationally known translational researcher. Her roles extended nationally, including group vice chair of the Alliance for Clinical Trials in Oncology and other positions within the American Association for Cancer Research, the American Society of Clinical Oncology and the National Cancer Institute.

Dr. Perez has authored more than 700 research articles in journals, books and abstracts and is invited frequently to lecture at national and international meetings. Dr. Perez serves on the editorial boards of multiple academic journals.



George Plitas, MD

Dr. Plitas is an Associate Attending Surgical Oncologist at the Memorial Sloan Kettering Cancer Center who specializes in the treatment of patients with breast cancer. He obtained his MD and general surgical training from the New York University Medical Center. He has also completed the Surgical Oncology Fellowship at MSKCC. Dr. Plitas holds the Jeanne A. Petrek Junior Faculty Chair and conducts translational immunology focused on determining how the tumor microenvironment shapes the phenotype and function of tumor resident immune cells.



Mark E. Robson, MD

Dr. Robson graduated from the University of Virginia School of Medicine in Charlottesville, Virginia, and did his internal medicine residency and hematology-oncology fellowship training at Walter Reed Army Medical Center in Washington DC. He is currently Chief of the Breast Medicine Service in the Department of Medicine at Memorial Hospital in New York, an attending physician on Breast Medicine and Clinical Genetics Services, and a Member of the Memorial Sloan Kettering Cancer Center. His clinical research has concentrated on the optimal application of germline information to the management of cancer patients, particularly those with breast cancer. He has been a lead investigator for a number of trials of PARP inhibitors in patients with BRCA mutation-associated breast cancer. In addition to developing PARP inhibition as a therapeutic strategy, he is currently developing new models for the acquisition of germline information, including "mainstreaming" through test ordering by primary oncology providers and broad genomic screening in the context of somatic mutational profiling. He is currently investigating the use of polygenic risk scores in facilitating decision-making among women with or without an inherited predisposition. He serves on the editorial board of the *Journal of Clinical Oncology* and is an associate editor for the *Journal of the National Cancer Institute*. He is past chair of the Ethics Committee of the American Society of Clinical Oncology and has served several terms on the ASCO Cancer Prevention Committee and its Cancer Genetics subcommittee.



Loren L. Rourke, MD, MHCM, FACS

Originally from the Northeast, Dr. Loren Rourke is a fellowship-trained breast surgical oncologist with extensive experience building comprehensive multidisciplinary breast programs in community, academic, and hybrid environments. She has dedicated her career to ensuring patients receive exceptional care in a compassionate and informative atmosphere. She completed her general surgery residency at the University of Tennessee in Knoxville, the Susan G. Komen Interdisciplinary Breast Fellowship at UT MD Anderson Cancer Center, and most recently a Master's in Healthcare Management from the Harvard T.C. Chan School of Public Health as part of her pursuit to broaden her business understanding of the current healthcare landscape. She currently serves as the first-ever Chief Surgical Officer for McKesson's US Oncology Network, a role dedicated to the improvement and strategic development of surgical services across the Network.



Andrew Seidman, MD

Dr. Andrew Seidman is the Medical Director, Bobst International Center, Professor of Medicine at Weill Cornell Medical College, an Attending Physician for the Breast Medicine Service at Memorial Sloan Kettering Cancer Center in New York City.

Dr. Seidman earned his medical degree from Hahnemann University School of Medicine in Philadelphia, Pennsylvania. He completed a residency in Internal Medicine at The Pennsylvania Hospital. Dr. Seidman then completed a fellowship in Medical Oncology and Hematology at Memorial Sloan Kettering Cancer Center in New York.

Dr. Seidman has authored or co-authored more than 200 peer-reviewed articles, reviews and book chapters, as well as over 150 abstracts, and he has served on the editorial boards of over a dozen leading journals. He has led pivotal clinical trials that inform the current use of paclitaxel and trastuzumab, amongst other agents, in the management of breast cancer. He has presented at innumerable national and international conferences and symposia on breast cancer related topics. He is currently a Principal Investigator on several clinical trials. Dr. Seidman has served as President of the American Society of Breast Disease, has received the Gay Clark Stoddard Award from the Susan G. Komen Foundation “in recognition of his compassion and commitment to the field breast health care and research”, and the Jacob Ehrenzeller Award for Academic Excellence. He is the recipient of a Career Development Award from ASCO, and has served on the ASCO Communications Committee. Dr. Seidman currently serves as Associate Chair, Academic Administration at MSKCC, and has an active research program focused on breast cancer brain metastases, and computer-assisted decision support in oncology, working with the MSK-IBM-Watson Team.



Tiffany A. Traina, MD

Dr. Tiffany A. Traina is an Associate Attending Physician on the Breast Medicine Service at Memorial Sloan Kettering Cancer Center. She serves as the Vice Chair, Oncology Care for the Department of Medicine; Clinical Director of the Breast Medicine Service; and is the Section Head of the Triple Negative Breast Cancer Clinical Research Program. She is also Associate Professor of Medicine at Weill Cornell Medicine in New York City. Her research program centers on the development of therapies for patients with breast cancer, with a particular focus on Triple Negative Breast Cancer and the role of the androgen receptor. Dr. Traina has served on numerous ASCO committees including the Scientific Program Committee for the ASCO Triple Negative Breast Cancer/Cytotoxics/Local Therapy track and she is the Chair-elect for the ASCO Membership Committee 2019-2020. Dr. Traina is a graduate of the 2016-2017 ASCO Leadership Development Program and now serves as an advisor on the Breast Cancer Guidelines Advisory Group. She is a founding member of the Translational Breast Cancer Research Consortium Triple Negative Breast Cancer Working Group. Her research efforts have led to many publications, peer-reviewed funding, and competitive funding from the Breast Cancer Research Foundation. She has received recognition for her teaching from Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine and has been acknowledged with the Hally Yaccino Steiner Award from the Susan G. Komen Breast Cancer Foundation and the Hero Award from the Triple Negative Breast Cancer Foundation.



Beth E. Whiteside, MD

Dr. Beth Whiteside is medical director of Albany Medical Center's Breast Care Center, which is accredited as a Breast Imaging Center of Excellence by the American College of Radiology. She also serves as assistant professor of radiology at Albany Medical College, and is a radiologist with ImageCare of Community Care Physicians, P.C. Dr. Whiteside was fellowship trained in breast imaging at Duke University. She completed her residency training at Hartford Hospital, and an internship at the then Mary Imogene Bassett Hospital in Cooperstown. She received her medical degree from the University at Buffalo School of Medicine and Biomedical Sciences.

2nd Annual BREAST CANCER SYMPOSIUM

Controversies in Breast Cancer: Increasing or Decreasing?

Notes

[illegible]

2nd Annual BREAST CANCER SYMPOSIUM

Controversies in Breast Cancer: Increasing or Decreasing?

is supported by educational grants from:

**Puma Biotechnology
Seattle Genetics**

Thank you to our Product Theater Sponsors:

September 25, 2020 – 10:15am Eastern Daylight Time

The non-CME Ancillary Event titled:

Navigating the HER2+ Breast Cancer Treatment Landscape: A Case-Based Clinical Discussion

is provided by:

Genentech, Inc.

A Member of the Roche Group

September 25, 2020 – 11:15am Eastern Daylight Time

The non-CME Ancillary Event titled:

*A CDK 4 & 6 Inhibitor With Overall Survival Data for Women With HR+,
HER2-Metastatic Breast Cancer, Including Those Likely to Do Worse*

is provided by:

Lilly USA, LLC

September 25, 2020 – 6:55pm Eastern Daylight Time

The non-CME Ancillary Event titled:

*Innovative Oral Treatment Options for Patients: HR+/HER2- mBC or
gBRCA Mutated Triple-Negative and HR+/HER2- mBC*

is provided by:

Pfizer Oncology

September 26, 2020 – 12:00pm Eastern Daylight Time

The non-CME Ancillary Event titled:

*Updates on the Treatment of Patients With Unresectable or
Metastatic HER2+ Breast Cancer Who Previously Received Anti-HER2 Therapies*

is provided by:

Daiichi Sankyo, Inc. and AstraZeneca

September 26, 2020 – 2:10pm Eastern Daylight Time

The non-CME Ancillary Event titled:

TUKYSA® (tucatinib): A New Treatment Option for Patients with HER2+ Metastatic Breast Cancer

is provided by:

Seattle Genetics

PROUDLY HOSTED BY



World class cancer care. Close to home.

ACTIVITY PLANNED BY



2nd Annual **BREAST CANCER SYMPOSIUM**

Controversies in Breast Cancer: Increasing or Decreasing?

Thank you to our Sponsors and Exhibitors:

GOLD SPONSORSHIP:

AstraZeneca PLC
Novartis Oncology

SILVER SPONSORSHIP:

Immunomedics
Lilly USA, LLC
Puma Biotechnology
Seattle Genetics

BRONZE SPONSORSHIP:

Amgen, Inc.
Biotheranostics, Inc.
Caris Life Sciences
Daiichi-Sankyo and AstraZeneca
Eisai Co., Ltd
Genentech, Inc.
GlaxoSmithKline
Guardant Health
Incyte Corporation
Merck & Co., Inc.
Myriad Genetics, Inc.
NeoGenomics Laboratories, Inc.
Pfizer, Inc.
Sanofi Genzyme

Thank you to our Conference Collaborators:

American Cancer Society HopeClub
Susan G. Komen® Upstate NY

PROUDLY HOSTED BY



World class cancer care. Close to home.

ACTIVITY PLANNED BY

